Skip to main content

Table 1 Subject Demographics

From: Quantification of lung water in heart failure using cardiovascular magnetic resonance imaging

 

Validation Cohort

Prospective Cohort

Normal

At-Risk

HFrEF

HFpEF

NYHA I/II

NYHA III/IV

NYHA I/II

NYHA III/IV

Patients, n

 

53

82

36

15

52

18

Male sex, n (%)*

19 (84)

16 (30)

44 (54)†

26 (72)†

6 (40)

30 (58)†

4 (22)

Age at CMR, years*

51 ± 13

65 ± 11

64 ± 10

66 ± 10

67 ± 16

68 ± 12

76 ± 9†

Height, cm*

173 ± 11

168 ± 9

170 ± 10

172 ± 10†

166 ± 9

170 ± 9

161 ± 11†

Weight, kg*

89 ± 21

70 ± 12

81 ± 16†

89 ± 19†

85 ± 18†

88 ± 15†

78 ± 19

BMI, kg/m2*

29 ± 7

25 ± 3

28 ± 5†

30 ± 5†

31 ± 7†

31 ± 5†

30 ± 8†

HR, min− 1

71 ± 22

70 ± 11

68 ± 13

72 ± 17

73 ± 12

69 ± 11

67 ± 12

Systolic BP, mmHg*

137 ± 23

131 ± 21

139 ± 19†

128 ± 21

121 ± 18

129 ± 18

132 ± 17

Diastolic BP, mmHg*

77 ± 15

76 ± 10

82 ± 13†

77 ± 18

71 ± 13

73 ± 14

74 ± 11

Comorbidities, n(%)

 Diabetes*

NA

0 (0)

19 (23)†

14 (39)†

7 (47)†

18 (35)†

8 (44)†

 Hypertension*

NA

0 (0)

74 (90)†

21 (58)†

8 (53)†

38 (73)†

15 (83)†

 CAD/MI*

NA

0 (0)

23 (28)†

22 (61)†

6 (40)†

16 (31)†

7 (39)†

 Current smoker*

NA

2 (4)

11 (13)

2 (6)

2 (13)

8 (15)*

0 (0)

 COPD*

NA

0 (0)

7 (9)†

5 (14)†

5 (33)†

8 (15)†

7 (39)†

 AFib*

NA

0 (0)

16 (20)†

13 (36)†

7 (47)†

24 (46)†

8 (44)†

Medications at baseline, n(%)

 Beta blocker*

NA

0 (0)

32 (39)†

32 (89)†

13 (87)†

43 (83)†

16 (89)†

 ACEi or ARB*

NA

0 (0)

64 (78)†

33 (92)†

14 (93)†

41 (79)†

16 (89)†

Laboratory results

 BNP, pg/ml*

505 ± 465

31 ± 20

53 ± 68†

244 ± 256†

381 ± 391†

144 ± 148†

265 ± 205†

 Creatinine, umol/L

NA

97 ± 140

82 ± 19

93 ± 25

98 ± 60

105 ± 43

100 ± 36

MRI measurements

 LVEF, %*

37 ± 18

63 ± 6

61 ± 9

32 ± 9†

34 ± 9†

56 ± 8†

59 ± 8†

 LVEDVi, ml/m2*

122 ± 56

70 ± 11

73 ± 19

119 ± 42†

115 ± 38†

75 ± 24

75 ± 22

 LV Massi, g/m2*

99 ± 35

52 ± 10

61 ± 14†

86 ± 23†

82 ± 23†

68 ± 13†

65 ± 14†

 LV Mass / LVEDV*

0.87 ± 0.25

0.76 ± 0.15

0.85 ± 0.16†

0.75 ± 0.17

0.74 ± 0.19

0.95 ± 0.23†

0.90 ± 0.22†

  1. Note: BNP, and creatinine were missing for 14 subjects. Missing values are not accounted for in reported statistics
  2. Abbreviations – HFrEF heart failure with reduced ejection fraction, HFpEF heart failure with preserved ejection fraction, NYHA New York Heart Association, CMR cardiovascular magnetic resonance imaging, BMI body mass index, HR heart rate, BP blood pressure, CAD/MI coronary artery disease/myocardial infarction, COPD chronic obstructive lung disease, ACEi angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, BNP b-type natriuretic peptide, LVEF left ventricular ejection fraction, LVEDVi indexed left ventricular end-diastolic volume, LV massi indexed left ventricular mass
  3. *p < 0.05 ANOVA comparison across the 6 groups of the Prospective Cohort; †p < 0.05 compared to normal controls